TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05108870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HB-201
Description: A anti-cancer vaccine that treats HPV-related cancers.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HB-201
Description: A anti-cancer vaccine that treats HPV-related cancers.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HB-201
Description: A anti-cancer vaccine that treats HPV-related cancers.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HB-201
Description: A anti-cancer vaccine that treats HPV-related cancers.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HB-202
Description: A anti-cancer vaccine that treats HPV-related cancers.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HB-202
Description: A anti-cancer vaccine that treats HPV-related cancers.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HB-202
Description: A anti-cancer vaccine that treats HPV-related cancers.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HB-202
Description: A anti-cancer vaccine that treats HPV-related cancers.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Chemotherapy drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Chemotherapy drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Chemotherapy drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Chemotherapy drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Chemotherapy drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Chemotherapy drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Chemotherapy drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Chemotherapy drug.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transoral Robotic Surgery
Description: Transoral robotic surgery is a procedure to remove mouth and throat cancers in which a surgeon uses a sophisticated, computer-enhanced system to guide the surgical tools.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transoral Robotic Surgery
Description: Transoral robotic surgery is a procedure to remove mouth and throat cancers in which a surgeon uses a sophisticated, computer-enhanced system to guide the surgical tools.
Study: NCT06469294

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Control (C) - Saline Gel
Description: After conventional periodontal treatment, saline gel will be applied in the periodontal pocket and, after 5 minutes, the laser application will be simulated with the device in inactive mode, in order to maintain blinding of the patients.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Control (C) - Saline Gel
Description: After conventional periodontal treatment, saline gel will be applied in the periodontal pocket and, after 5 minutes, the laser application will be simulated with the device in inactive mode, in order to maintain blinding of the patients.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Test (t) - Photodynamic therapy and 2% chlorexidine and 0,005% methylene blue
Description: After conventional periodontal treatment, photosensitization will be performed with 2% chlorhexidine gel with 0.005% methylene blue (Fórmula e Ação Farmácia, São Paulo, SP, Brasil) for 5 minutes and photodynamic therapy will be applied with a rede laser (660nm) usinf DuoⓇ laser (MMOptics, São Carlos, SP, Brazil) with the optical fiber inside the periodontal pocket in back and forth movements, according to the manufacturer's protocol, for 90s, 9 joules of energy, dose of 508.5J/cm2, irradiance of 5.65W/cm2 and power of 100mW.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Test (t) - Photodynamic therapy and 2% chlorexidine and 0,005% methylene blue
Description: After conventional periodontal treatment, photosensitization will be performed with 2% chlorhexidine gel with 0.005% methylene blue (Fórmula e Ação Farmácia, São Paulo, SP, Brasil) for 5 minutes and photodynamic therapy will be applied with a rede laser (660nm) usinf DuoⓇ laser (MMOptics, São Carlos, SP, Brazil) with the optical fiber inside the periodontal pocket in back and forth movements, according to the manufacturer's protocol, for 90s, 9 joules of energy, dose of 508.5J/cm2, irradiance of 5.65W/cm2 and power of 100mW.
Study: NCT05034497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 186RNL
Description: All participants will be required to have an Ommaya Reservoir and a CSF Flow Study.~Participants will receive a single 5cc dose of 186RNL via Ommaya Reservoir.
Study: NCT06105502

Intervention type: BEHAVIORAL
Intervention: Psychotherapy education
Description: Psychotherapy education, including supervision, lectures, and workshops
Study: NCT05418088

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CD19/CD20/CD22 CAR T-Cells
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CD19/CD20/CD22 CAR T-Cells
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV
Study: NCT05625737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib
Description: Fruquintinib will be administrated as 4mg orally, once daily for 2 weeks on/1 week off.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab will be administrated as 200mg once every 3 weeks.
Study: NCT05655598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib Oral Product
Description: 125 mg/day (FDA approved dose) or the last tolerated dose before progression for 21 days of a 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib Oral Product
Description: 125 mg/day (FDA approved dose) or the last tolerated dose before progression for 21 days of a 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib Oral Product
Description: 125 mg/day (FDA approved dose) or the last tolerated dose before progression for 21 days of a 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-116
Description: 120 mg/day, 5 days on 2 days off, for days 1-28 of a 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-116
Description: 80 mg/day, 5 days on 2 days off, for days 1-28 of a 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-116
Description: 40 mg/day, 5 days on 2 days off, for days 1-28 of a 28 day cycle
Study: NCT06577896

Intervention type: DEVICE
Intervention: Onyx family
Description: Safety and Efficacy of 1-Month DAPT in Elderly Patients at High Risk of Ischemia and Bleeding After Percutaneous Coronary Intervention with Onyx Family Stents

Intervention type: DEVICE
Intervention: Onyx family
Description: Safety and Efficacy of 1-Month DAPT in Elderly Patients at High Risk of Ischemia and Bleeding After Percutaneous Coronary Intervention with Onyx Family Stents

Intervention type: DEVICE
Intervention: Onyx family
Description: Safety and Efficacy of 1-Month DAPT in Elderly Patients at High Risk of Ischemia and Bleeding After Percutaneous Coronary Intervention with Onyx Family Stents

Intervention type: DEVICE
Intervention: Onyx family
Description: Safety and Efficacy of 1-Month DAPT in Elderly Patients at High Risk of Ischemia and Bleeding After Percutaneous Coronary Intervention with Onyx Family Stents

Intervention type: DEVICE
Intervention: Onyx family
Description: Safety and Efficacy of 1-Month DAPT in Elderly Patients at High Risk of Ischemia and Bleeding After Percutaneous Coronary Intervention with Onyx Family Stents
Study: NCT05501236

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Grass S88 Muscle Stimulator
Description: The Grass S88 nerve and muscle stimulator is a widely-used tool in electromyography and nerve conduction studies. During the DISE and second sleep study, fine-wire electrodes will be placed into the hypoglossal nerve or genioglossus muscle. Two more electrodes are placed transcutaneously, proximate to the bilateral branches of the cervicalis innervating the sternothyroid muscle in the anterior neck.
Study: NCT05915806

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High-dose DHA
Description: Direct enteral DHA supplementation at a dose of at least 40 mg/kg/day or DHA supplementation of breast milk or formula aiming for at least 0.4% of total fatty acids.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Control with no or low-dose DHA.
Study: NCT06354647

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Zirconia-based primary anterior crowns with retention grooves
Description: Zirconia-based primary anterior crowns with retention grooves

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Zirconia-based primary anterior crowns without retention grooves
Description: Zirconia-based primary anterior crowns without retention grooves
Study: NCT05992675

Intervention type: DEVICE
Intervention: Lotrafilcon A contact lenses
Description: CE-marked silicone hydrogel contact lenses

Intervention type: DEVICE
Intervention: Balafilcon A contact lenses
Description: CE-marked silicone hydrogel contact lenses
Study: NCT06120712

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC101 TIL
Description: Patients with advanced, recurrent or metastatic melanoma (excluding uveal melanoma) who have failed standard treatment such as PD-1 antibodies (if BRAF mutation is present, BRAF and MEK inhibitors have failed) and are ineligible for resection.
Study: NCT06176118

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 2-HOBA
Description: 2-HOBA supplement take three times daily for 12-weeks
Study: NCT06292169

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pectoralis Minor Release
Description: The pectoralis minor is a muscle on the anterior chest wall attaching to the coracoid process. In the group undergoing pectoralis minor release, through the same deltopectoral incision that will not be extended or different as compared to the RSA only group, the pec minor will be exposed on the medial aspect of the coracoid at the upper part of the incision. It will be cut from its insertion on the coracoid while being careful to protect any neurovascular structures.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RSA
Description: RSA is the current Standard of Care (SOC)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RSA
Description: RSA is the current Standard of Care (SOC)
Study: NCT06576505

Intervention type: PROCEDURE
Intervention: peripheral blood sampling, bronchoscopy, upper airway and faeces sampling
Description: 1. Repeated peripheral blood sampling at diagnostic and follow-up visits, in total a maximum of 400 ml/year but never more than 100 ml/ month.~2. Upper airway sampling wih swab, aspirate and curettage, maximum 3 times/year.~3. Faeces sampling, the patients do this themselves and leave it to the research unit, maximum 3 times/year.~4. Bronchoscopy with lavage and a maximum of 6 mucosal biopsies before and after 6-12 months treatment.
Study: NCT06465524

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-intensity laser therapy
Description: High-intensity laser therapy (HILT), also referred to as Class IV laser therapy, involves the administration of collimated and monochromatic electromagnetic radiation within the infrared or red spectrum. It operates at power levels exceeding 500 milliwatts (0.5 W), leveraging both photobiomodulation and thermal effects. This distinguishes HILT from Class III lasers (low-level laser therapy, or LLLT), which lack photothermal effects when operating below 500 mW.
Study: NCT06175338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 1000 mg in 150 ml 0,9 % NaCl (total volume of infusion 250 ml)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MabThera®
Description: MabThera® 1000 mg in 150 ml 0,9 % NaCl (total volume of infusion 250 ml)
Study: NCT05795179

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cold-Pressor Task (CPT)
Description: CPT is a physiological stress task in which participants continuously submerge their hand and forearm in ice-water (0-4°C) for 3 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trier Social Stress Test (TSST)
Description: The TSST is a psychosocial stressor that requires participants perform a short speech and solve math problems in front of 2 evaluative judges.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Modified Non-Stress CPT
Description: The modified non-stress CPT involves participants continuously submerging their hand and forearm in warm water for 3 minutes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Modified Non-Stress TSST
Description: For the modified non-stress TSST, participants are asked to prepare for a speech that they will practice alone to themselves and complete math problems alone on a piece of scrap paper.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Functional Magnetic Resonance Imaging (fMRI)
Description: Participants will complete the self-control task in the fMRI scanner.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional Magnetic Resonance Imaging (fMRI)
Description: Participants will complete the self-control task in the fMRI scanner.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Functional Magnetic Resonance Imaging (fMRI)
Description: Participants will complete the self-control task in the fMRI scanner.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional Magnetic Resonance Imaging (fMRI)
Description: Participants will complete the self-control task in the fMRI scanner.
Study: NCT05468814

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Z-plasty
Description: It is a surgical technique in which a Z-shaped section of the transverse carpal ligament is performed, to later join both ends with a resorbable stitch.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional
Description: It is a surgical technique in which a complete section of the transverse carpal ligament is performed, without subsequent closure.
Study: NCT04986007

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Cognitive Behavioral Therapy for Insomnia
Description: Digital cognitive behavioral therapy for insomnia is an automated, internet-based delivery system for the core components of cognitive behavioral therapy for insomnia (CBT-I). For this trial, dCBT-I will be delivered using Sleep Healthy Using the Internet (SHUTi), which delivers the core content of CBT-I in 6 interactive lessons called Cores: Getting Ready; Sleep Scheduling; Sleep Practices; Thinking Differently; Sleep Hygiene; and Moving On. The primary therapeutic approaches deployed through these cores are stimulus control and sleep restriction. The minimum acceptable dose for this study is completion of 4 out of 6 cores; completion of fewer than 4 cores will be considered a dropout.
Study: NCT05228574

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sodium chloride (NaCl)
Description: Sodium chloride capsules 6 grams per day for 4 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules, 6 grams per day for 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amiloride Hcl 5mg Tab
Description: Amiloride 5mg tablets, 20 mg per day for two weeks in open-label setting.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Amiloride Hcl 5mg Tab
Description: Amiloride 5mg tablets, 20 mg per day for two weeks in open-label setting.
Study: NCT04888624

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DrySee® dressing with moisture detection
Description: DrySee® is a waterproof bandage designed to protect surgical incisions. It contains an indicator at the perimeter of the dressing, and at the wound site that turns blue when it comes into contact with liquid (figure 1). The indicator identifies a break in the integrity of the postoperative dressing. Changing the dressing at this point prevents bacteria from reaching the incision reducing the risk of infection. In addition, the waterproof dressing allows patients to shower or bath following surgery.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tegaderm® + Pad transparent film dressing
Description: Tegaderm® is a transparent adhesive dressing commonly used as a postoperative dressing. The dressing has been shown to be superior to gauze in reducing SSIs. Tegaderm®, like DrySee,® is waterproof; however, it lacks technology that identifies a breach in dressing integrity.
Study: NCT05042674

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Placebo
Description: after a blood draw placebo will be consumed followed by 2 additional blood draws

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Ergothioneine, 25 miligrams
Description: after a blood draw 25 miligrams of ergothioneine will be consumed followed be 2 additional blood draws

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Ergothioneine, 25 miligrams, daily for 1 week
Description: a blood draw will be administered after a week of consuming 25mg ergothioneine daily
Study: NCT06236906

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device supported behavioural treatment
Description: The method involves behavioral change supported by a digital support system, including daily home weighings, a clear weight curve in a mobile app, and communication with the treatment team through the same app.
Study: NCT04921982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: Oral administration of Propranolol, 90 minutes prior to a brief memory reactivation session, performed by a trained nurse once a week for six consecutive weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration of Placebo, 90 minutes prior to a brief memory reactivation session, performed by a trained nurse, once a week for six consecutive weeks.
Study: NCT04932395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anshen Buxin Liuwei Pill
Description: 15 capsules/time, 2 times/day, orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo simulated as the Anshen Buxin Liuwei Pills with same appearance，smell and taste,15 capsules/time, 2 times/day, orally.
Study: NCT04672642

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SpyGlass DS
Description: Detection by the SpyGlass DS of residual pancreatic stones not detected by the standard method (CT scan and ERCP)
Study: NCT04324034

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: vNOTES
Description: vaginal Natural Orifice Transluminal Endoscopic Surgery (vNOTES) is vaginal surgery with a natural approach. The GelPOINT V-path transvaginal access platform is used. It is a device designed to be placed transvaginally to establish a pathway for the insertion of minimally invasive instruments while maintaining insufflation to perform diagnostic or operative procedures. This device also allows a passage for the extraction of operating parts.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopy
Description: The surgery by conventional laparoscopy is used
Study: NCT06437587

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based rehabilitation appropriate technology (S-HRAT) training
Description: The S-HRAT training instruction consists of two phases: in-hospital training and post-discharge remote home training. Based on the S-HRAT list, we select individualized home rehabilitation training exercises for the participants and conduct five offline training instruction sessions one week before discharge to ensure that the participants master the correct method for each exercise and clarify precautions. At discharge, participants will receive an S-HRAT brochures, which will include detailed text, pictures and video demonstrations of exercises, to visualize the rehabilitation instructions and make them easy to understand. Participants learn how to use the S-HRAT booklet and follow a daily training program to complete the prescribed content. They will be asked to record a video of their training and send it to the researcher via WeChat for monitoring purposes and feedback.
Study: NCT05623124

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT06091163

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ketogenic Diet
Description: A Ketogenic Diet (KD) is a high-fat and very low-carbohydrate intake. Participants will follow a modified KD (estimated 20-50g carbohydrates/day based on a 2000 kcal diet) without energy restriction. Participants will test for ketosis in their morning urine at least twice a week to monitor adherence.~To support adherence in people with depression, delivered pre-prepared KD meals (3 meals per day) and additional ketogenic snacks will be sent to participants. A registered dietitian will provide weekly 30-minute nutritional counselling sessions. The dietitian will schedule appointments and assess the participants' experience with adhering to the KD diet, troubleshoot as required, give guidance on how to prevent or overcome side effects of KD diets, and keep record of participants' ketosis level and suicide risk.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Phytonutrient Diet
Description: Participants in the control group will receive the same degree of dietetic input and be told that their diet is a modified fat and phytonutrient diet. The photo diet aims to increase vegetable consumption, reduce saturated fat intake and increase poly- and mono-unsaturated fat intake. Participants in the control group will receive food vouchers (£20 every two weeks) to help purchase these items. This aims to be a plausible placebo dietary treatment for depression. There is no clear evidence that these manipulations will change depression severity. The dietitian will create written materials to explain the diet and suggest foods by colour with supporting recipe suggestions.
Study: NCT06348927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunvozertinib in combination with Anlotinib
Description: Drug: Sunvozertinib combination with Anlotinib~Sunvozertinib 300 mg once daily (QD) with Anlotinib 8mg once daily （QD in Day 1-14），21 days in one cycle.